Delta Asia International Corporation (TPEX:6762)
196.00
+5.00 (2.62%)
Dec 5, 2025, 1:00 PM CST
Delta Asia International Revenue
Delta Asia International had revenue of 175.52M TWD in the quarter ending September 30, 2025, with 5.97% growth. This brings the company's revenue in the last twelve months to 711.19M, up 39.69% year-over-year. In the year 2024, Delta Asia International had annual revenue of 580.51M with 14.27% growth.
Revenue (ttm)
711.19M
Revenue Growth
+39.69%
P/S Ratio
9.69
Revenue / Employee
3.89M
Employees
183
Market Cap
6.89B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 580.51M | 72.49M | 14.27% |
| Dec 31, 2023 | 508.02M | 45.05M | 9.73% |
| Dec 31, 2022 | 462.97M | -68.34M | -12.86% |
| Dec 31, 2021 | 531.32M | -23.00M | -4.15% |
| Dec 31, 2020 | 554.31M | 170.94M | 44.59% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Caliway Biopharmaceuticals | 34.99M |
| PharmaEssentia | 13.82B |
| Heron Neutron Medical | 5.53M |
| Lotus Pharmaceutical | 18.66B |
| Bora Pharmaceuticals Co., LTD. | 21.10B |
| Oneness Biotech | 117.33M |
| Lumosa Therapeutics | 42.59M |
| Center Laboratories | 1.57B |